MG-ADL scores improved, indicating enhanced daily functioning for patients with myasthenia gravis. Limitations include potential coding errors, selection biases, and missing clinical data ...

Ultomiris (ravulizumab-cwvz) is a brand-name infusion prescribed for myasthenia gravis. This article covers topics such as side effects, dosage, and how Ultomiris works. Ultomiris is an ...

Samantha Ruth Prabhu, who was diagnosed with myositis, has recently shared an update about her health. In a recent interview, Sam admitted that an autoimmune disorder affected her physically and ...

Robert "Bob" O. Glaesman, 82, of Willmar, died on April 7 at Bethesda Grand following a courageous fight against Inclusion Body Myositis (IBM). Funeral services will be held at 11 a.m. on Monday ...

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around. Researchers have ...

According to the presented data, among the participants in the Telitacicept 240 mg group, 98.1% of the patients demonstrated a ≥ 3-point reduction in Myasthenia Gravis Activities of Daily Living ...

New topline data from the MINT trial (NCT04524273), which is investigating inebilizumab in patients with generalized myasthenia gravis who are acetylcholine receptor (AChR) antibody or muscle ...

Remegen Co. Ltd. emerged as a surprise challenger in the generalized myasthenia gravis space, unveiling positive phase III data of its China-approved lupus drug, telitacicept (RCT-18; Tai’ai), in the ...

US biotech Cartesian Therapeutics (Nasdaq: RNAC) has reported that patients with generalized myasthenia gravis (gMG) continued to experience lasting symptom relief 12 months after treatment with its ...

There is no guarantee that they will become commercially available for the use(s) under investigation. * Myasthenia Gravis Foundation of America (MGFA) Class II-IV gMG and likely not in need v of a ...

Carte­sian Ther­a­peu­tics said its au­tol­o­gous CAR-T ther­a­py has shown “sus­tained ben­e­fits” in peo­ple with a rare au­toim­mune dis­ease, ac­cord­ing to the lat­est ...